157 related articles for article (PubMed ID: 37987969)
21. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
22. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
[TBL] [Abstract][Full Text] [Related]
23. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
24. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
[TBL] [Abstract][Full Text] [Related]
25. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
26. [
Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
[TBL] [Abstract][Full Text] [Related]
27. Correlations of the
Karyagar SS; Karyagar S; Guven O
Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
[TBL] [Abstract][Full Text] [Related]
28. An Unexpected Seminal Vesicle Pitfall in PSMA PET.
Bronte A; Rosales JJ; Torres Roca M; Miñana B; Rodríguez-Fraile M
Clin Nucl Med; 2024 Jun; 49(6):e274-e275. PubMed ID: 38537177
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and preclinical evaluation of an Al
Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
[TBL] [Abstract][Full Text] [Related]
30. [Ga-68-PSMA PET/CT for prostate cancer].
Hellwig D; Moosbauer J; Eilles C
Aktuelle Urol; 2014 Nov; 45(6):457-63. PubMed ID: 25518963
[TBL] [Abstract][Full Text] [Related]
31. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
Taywade SK; Damle NA; Bal C
Clin Nucl Med; 2016 May; 41(5):e263-5. PubMed ID: 26914556
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
33. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
34. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
[TBL] [Abstract][Full Text] [Related]
35. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
37. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
38.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
39. Total-Body
Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
